DMARDs

Overview

No overview information available.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
Cortisol Circadian Rhythm in Patients With RA	2023/01/04	NCT05671627	N/A	Recruiting	National and Kapodistrian University of Athens
Immunosuppressant Combined With Pirfenidone in CTD-ILD	2021/06/16	NCT04928586	Phase 4	Active, not recruiting	Qilu Hospital of Shandong University
PANLAR's Latin American Registry of Rheumatic Patients Treated With Jak Inhibitors	2021/03/29	NCT04821206	N/A	UNKNOWN	Liga Panamericana de Asociaciones de Reumatologia (PANLAR)
Optimal MTX Dose With Folic Acid Randomized Case-control Trial	2019/08/26	NCT04066803	Phase 4	UNKNOWN	Sun Yat-sen University
Rheumatoid Arthritis Memory B Cells and Abatacept	2018/08/31	NCT03652961	Phase 4	Completed	NYU Langone Health
Human Umbilical Cord-Mesenchymal Stem Cells for Rheumatoid Arthritis	2015/12/31	NCT02643823	Phase 1	UNKNOWN	Shenzhen Hornetcorn Bio-technology Company, LTD
An Observational Study of Infliximab in Participants Suffering From Ankylosing Spondylitis With Hip Involvement	2014/11/18	NCT02293681	N/A	Terminated	Janssen Research & Development, LLC
A Study of Tocilizumab (RoActemra/Actemra) in Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Participants With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biologic DMARD Therapy or the First Anti-TNF Biologic Agent	2014/01/28	NCT02046603	Phase 3	Completed	Hoffmann-La Roche
A Study to Evaluate Efficacy of Tocilizumab Administered as Monotherapy or in Combination With Methotrexate and/or Other Disease Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis (RA) Participants	2013/09/13	NCT01941940	Phase 3	Completed	Hoffmann-La Roche
A Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicentre, Phase III Study to Evaluate the Efficacy and Safety of ENIA11 in Combination With DMARDs Versus DMARDs Alone in Patients With Rheumatoid Arthritis	2013/02/08	NCT01787149	Phase 3	UNKNOWN	Mycenax Biotech Inc.

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

Related News

SetPoint Medical Seeks FDA Approval for Novel Neuromodulation Device in Rheumatoid Arthritis

7 months ago

• SetPoint Medical has submitted a Premarket Approval (PMA) application to the FDA for its neuroimmune modulation device targeting rheumatoid arthritis (RA). • The device stimulates the vagus nerve to activate anti-inflammatory pathways, offering a potential alternative for RA patients who don't respond to traditional treatments. • The PMA submission is backed by positive data from the RESET-RA clinical study, which demonstrated the device's safety and effectiveness. • SetPoint's system has received Breakthrough Device Designation from the FDA, potentially expediting the review process.

Help Us Improve

Your feedback helps us provide better drug information and insights.

AI-Powered Research

Premium Access